INDP

Indaptus Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website indaptusrx.com
Employees(FY) 6
ISIN US45339J1051

Performance

+10.79%

1W

-17.2%

1M

+41.72%

3M

+7.44%

6M

+31.25%

YTD

+12.68%

1Y

Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of INDP 2024-05-10

Overview:

In analyzing the technical indicators for INDP over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for potential in...

See more ...

Recent News & Updates

2024-05-08 00:54
INDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-07 20:00
Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-04-10 19:30
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting(Globenewswire)
2024-03-27 20:00
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference(Globenewswire)
2024-03-24 20:30
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting(Globenewswire)
2024-03-17 20:00
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024(Globenewswire)
2024-03-12 19:30
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update(Globenewswire)
2024-03-03 18:30
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort(Globenewswire)
2024-02-14 19:00
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference(Globenewswire)
2024-02-07 19:00
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels(Globenewswire)
2024-01-03 19:00
European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology(Globenewswire)
2023-11-06 03:01
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update(Globenewswire)
2023-11-05 19:00
Indaptus Therapeutics' Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study(Globenewswire)
2023-10-30 21:01
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting(Globenewswire)
2023-09-26 20:00
Indaptus Therapeutics to Present at the LD Micro Main Event XVI(Globenewswire)
2023-09-25 20:00
Registration Is Now Open For Tribe Publics Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics CEO On Friday, September 29, 2023(Yahoo Finance)
2023-09-18 20:00
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20(Yahoo Finance)
2023-09-05 20:05
Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-13 20:00
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update(Yahoo Finance)
2023-08-09 20:45
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20(Yahoo Finance)
2023-08-06 20:00
Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer(Yahoo Finance)
2023-06-14 20:00
Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference(Yahoo Finance)
2023-05-30 20:30
Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023(Yahoo Finance)
2023-05-10 19:00
Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update(Yahoo Finance)
2023-05-08 20:00
Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform(Yahoo Finance)
2023-04-30 20:00
Indaptus Therapeutics Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit(Yahoo Finance)
2023-04-23 21:00
Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV(Yahoo Finance)
2023-04-20 04:05
Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023(Yahoo Finance)
2023-04-18 21:28
UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023(Yahoo Finance)
2023-04-18 20:05
Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023(Yahoo Finance)

Page 1 of 3

previousnext